Hugo Alves-Figueiredo PhD , Christian Silva-Platas PhD , Manuel Estrada PhD , Yuriana Oropeza-Almazán PhD , Martin Ramos-González MD, PhD , Judith Bernal-Ramírez PhD , Eduardo Vázquez-Garza MD, PhD , Armando Tellez PhD , Felipe Salazar-Ramírez MD, MSc , Abraham Méndez-Fernández MSc , José Luis Galaz MD , Pedro Lobos PhD , Keith Youker PhD , Omar Lozano PhD , Guillermo Torre-Amione MD, PhD , Gerardo García-Rivas PhD
{"title":"Mitochondrial Ca2+ Uniporter–Dependent Energetic Dysfunction Drives Hypertrophy in Heart Failure","authors":"Hugo Alves-Figueiredo PhD , Christian Silva-Platas PhD , Manuel Estrada PhD , Yuriana Oropeza-Almazán PhD , Martin Ramos-González MD, PhD , Judith Bernal-Ramírez PhD , Eduardo Vázquez-Garza MD, PhD , Armando Tellez PhD , Felipe Salazar-Ramírez MD, MSc , Abraham Méndez-Fernández MSc , José Luis Galaz MD , Pedro Lobos PhD , Keith Youker PhD , Omar Lozano PhD , Guillermo Torre-Amione MD, PhD , Gerardo García-Rivas PhD","doi":"10.1016/j.jacbts.2024.01.007","DOIUrl":null,"url":null,"abstract":"<div><p>The role of the mitochondrial calcium uniporter (MCU) in energy dysfunction and hypertrophy in heart failure (HF) remains unknown. In angiotensin II (ANGII)–induced hypertrophic cardiac cells we have shown that hypertrophic cells overexpress MCU and present bioenergetic dysfunction. However, by silencing MCU, cell hypertrophy and mitochondrial dysfunction are prevented by blocking mitochondrial calcium overload, increase mitochondrial reactive oxygen species, and activation of nuclear factor kappa B–dependent hypertrophic and proinflammatory signaling. Moreover, we identified a calcium/calmodulin–independent protein kinase II/cyclic adenosine monophosphate response element–binding protein signaling modulating MCU upregulation by ANGII. Additionally, we found upregulation of MCU in ANGII-induced left ventricular HF in mice, and in the LV of HF patients, which was correlated with pathological remodeling. Following left ventricular assist device implantation, MCU expression decreased, suggesting tissue plasticity to modulate MCU expression.</p></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":null,"pages":null},"PeriodicalIF":8.4000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2452302X24000111/pdfft?md5=33f5014a0200ad9d38463fc1925dcf56&pid=1-s2.0-S2452302X24000111-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC: Basic to Translational Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452302X24000111","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
The role of the mitochondrial calcium uniporter (MCU) in energy dysfunction and hypertrophy in heart failure (HF) remains unknown. In angiotensin II (ANGII)–induced hypertrophic cardiac cells we have shown that hypertrophic cells overexpress MCU and present bioenergetic dysfunction. However, by silencing MCU, cell hypertrophy and mitochondrial dysfunction are prevented by blocking mitochondrial calcium overload, increase mitochondrial reactive oxygen species, and activation of nuclear factor kappa B–dependent hypertrophic and proinflammatory signaling. Moreover, we identified a calcium/calmodulin–independent protein kinase II/cyclic adenosine monophosphate response element–binding protein signaling modulating MCU upregulation by ANGII. Additionally, we found upregulation of MCU in ANGII-induced left ventricular HF in mice, and in the LV of HF patients, which was correlated with pathological remodeling. Following left ventricular assist device implantation, MCU expression decreased, suggesting tissue plasticity to modulate MCU expression.
期刊介绍:
JACC: Basic to Translational Science is an open access journal that is part of the renowned Journal of the American College of Cardiology (JACC). It focuses on advancing the field of Translational Cardiovascular Medicine and aims to accelerate the translation of new scientific discoveries into therapies that improve outcomes for patients with or at risk for Cardiovascular Disease. The journal covers thematic areas such as pre-clinical research, clinical trials, personalized medicine, novel drugs, devices, and biologics, proteomics, genomics, and metabolomics, as well as early phase clinical trial methodology.